Cerecor Receives Fast Track Designation from FDA for CERC-802
Cerecor (NASDAQ:CERC) has announced that the US Food and Drug Administration has granted the company fast track designation for CERC-802...
Cara Therapeutics and Enteris BioPharma Enter Commercial License Agreement
Cara Therapeutics (NASDAQ:CARA) has announced it has entered into a license agreement with Enteris BioPharma for oral formulation rights to...
Aptinyx Presents Data of NYX-458 in Preclinical Model of Head Injury
Aptinyx (NASDAQ:APTX) has announced presentation of preclinical data on its novel NMDA receptor modulator, NYX-458. As quoted in te press...
Lexaria Announces Commercial Launch of ChrgD+ Odorless, Flavorless, Water-Soluble Powdered Hemp Oil
Lexaria Bioscience Corp. (OTC:LXRP, CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce...
Tonix Pharmaceuticals Expands Preclinical Pipeline
Tonix Pharmaceuticals Holding (NASDAQ:TNXP) has announced an exclusive agreement to in-license a triple reuptake inhibitor, TNX-1600, to treat post-traumatic stress...
Mersana Therapeutics Expands Study of XMT-1536
Mersana Therapeutics (NASDAQ:MRSN) has announced it has dosed the first patient in its Phase 1 study of XMT-1536 in patients...
Outlook Therapeutics Finishes Patient Enrollment for NOrse 1 Phase 3 Clinical Trial
Outlook Therapeutics (NASDAQ:OTLK) has announced it has finished enrolling patients in its NORSE i Phase 3 clinical trial evaluating ONS-5010...